Mylene LANG

Dr. Mylene LANG

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
VSVictoria Susan
Victoria Susan
MLMylene LANG
Mylene LANG
MSMarcela SABOU
Marcela SABOU
LBLine M Bourel-Bonnet
Line M Bourel-Bonnet
Invasive fungal infections (IFIs) are one of the most significant public health challenges worldwide. Yet, research and communication thereof were left behind for a long time, until the WHO published a priority pathogens list to guide research, development, and public health action in October 2022. Indeed, due to the rising number of immunocompromised patients at risk and the high level of morbidity, mortality, and economic burden they entail, especially in low- and middle-income countries, IFIs are a serious public health threat. Fungal infections due to dimorphic fungi face additional challenges such as limited knowledge outside of endemic areas and restricted availability of antifungal molecules in areas affected by these infections. The number of related deaths per year is estimated at 2.5 million, but non-governmental organisations make a wider estimation, due to the difficulties in early in vitro diagnostic and troublesome collection and analysis of epidemiological data. Despite this fact, the therapeutic toolbox addressing these infections remains limited, with only four main families of molecules available so far. The antifungal therapeutic supply is composed of very toxic polyenes, the weakly selective and nearly unused 5-fluorocytosine, and azoles, some of which are becoming increasingly inefficient against IFIs. In the 2000–2020s, the fourth arising family consisted of safer semisynthetic echinocandins. Unfortunately, nowadays, more and more fungal isolates encountered in intensive care units exhibit a low susceptibility to echinocandins or are even multiresistant. In this review, we expose the current treatments available to fight against invasive fungal infections. We recall the discovery and physico-chemical aspects of these substances leading to structure/activity and structure/properties relationships. We particularly focus on the to-date resistances and their molecular mechanisms. We finally list some of the most relevant antifungal drug candidates, as they were freshly overviewed by the World Health Organization in April 2025, highlighting the importance of the molecular dimension of this pursuit toward the expansion of the antifungal therapeutic toolbox.

21 September 2023 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
HLHaijuan Liu
Haijuan Liu
MLMylene LANG
Mylene LANG
DHDamien Hazelard
Damien Hazelard
Philippe CompainPhilippe Compain
Philippe Compain

19 February 2024 in Chemical Communications
Verified
Journal Article
Open access
PDF file
MLMylene LANG
Mylene LANG
DTDamien Tardieu
Damien Tardieu
BPBenoit Pousse
Benoit Pousse
Philippe CompainPhilippe Compain
Philippe Compain
NKNicolas Kern
Nicolas Kern
Novel C,C-glycosyl amino acids were accessed by means of an iron-catalyzed hydrogen atom transfer sequence. Crucially, two-fold diastereocontrol could be achieved in the ‘matched’ coupling of exo-d-glycals with an enantiopure dehydroalanine acceptor.

1 February 2021 in Carbohydrate Polymers
Verified
Journal Article
Closed access
SMSophie Morin
Sophie Morin
BLBrieuc Lecart
Brieuc Lecart
MLMylene LANG
Mylene LANG
ARAurore Richel
Aurore Richel

13 October 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
MLMylene LANG
Mylene LANG
SRStéphanie Riché
Stéphanie Riché
LBLucie Brendel
Lucie Brendel
CLClémentine Leger
Clémentine Leger
RHRomain Hany
Romain Hany
LBLine M Bourel-Bonnet
Line M Bourel-Bonnet
Echinocandins (ECs) are semisynthetic lipocyclohexapeptides introduced in the 2000s to treat invasive fungal infections. They selectively and safely inhibit fungal β-(1,3)-D-glucan synthase, a key enzyme for fungal cell wall integrity, but their precise mechanism remains unclear. Their widespread use has led to emerging resistances, underscoring the need for molecular probes to investigate their action and resistance mechanisms. Due to their structural complexity, only few total syntheses and very limited fluorescent analogues have been reported. Here, we present a solid-phase peptide synthesis (SPPS) strategy to readily access to the EC pharmacophore and to novel fluorescent analogues. Using a safety-catch linker resin, cyclization and cleavage are efficiently combined, affording high-purity cyclic lipopeptides with simplifiedpurification step. Depending on the design, fluorescent tags were introduced either on-resin or in solution via bioconjugation. Several analogues retained antifungal activity against Candida albicans, and their interaction with fungal cells was visualized by confocal microscopy. This versatile methodology delivers some of the first fully synthetic fluorescent echinocandins, providing powerful tools to explore their mechanisms of action and fungal resistance.